Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 2/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | LYPLA1 | O75608 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489664 | 0.84 | MAPT (0.50) | BBOX1ALDH1A1TSHRGMNNLMNA | |
| SCHEMBL28495272 | 0.76 | GMNN (0.40) | BBOX1ALDH1A1TSHRGMNNLMNA | |
| SCHEMBL917845 | 0.74 | ALDH1A1 (0.67) | BBOX1ALDH1A1TSHRGMNNLMNA | |
| Eprodisate SCHEMBL293813 | 0.74 | ALDH1A1 (0.67) | BBOX1ALDH1A1TSHRGMNNLMNA | |
| SCHEMBL14885533 | 0.74 | ALDH1A1 (0.45) | ALDH1A1TSHRLMNATP53ALOX15 | |
| SCHEMBL30834792 | 0.73 | ALDH1A1 (0.39) | ALDH1A1TSHRALOX15CA12CA2 | |
| SCHEMBL28277907 | 0.73 | GMNN (0.38) | BBOX1ALDH1A1TSHRGMNNLMNA | |
| SCHEMBL15793454 | 0.72 | ALDH1A1 (0.43) | ALDH1A1TSHRALOX15CA12CA2 | |
| SCHEMBL128907 | 0.72 | APP (0.46) | ALDH1A1TSHRLMNAALOX15MAPT | |
| SCHEMBL3910116 | 0.72 | ALDH1A1 (0.43) | ALDH1A1TSHRALOX15CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393875-B2 | Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-07-01 | — | — | US | claimed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | claimed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | claimed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | claimed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-05-20 | — | — | US | disclosed |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | QUEEN'S UNIVERSITY | 2002-12-19 | — | — | US | disclosed |
| US-6310073-B1 | ADMINISTERING TO SUBJECT THERAPEUTICALLY EFFECTIVE AMOUNT OF 3-AMINO-1-PROPANESULFONIC ACID, OR PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, SUCH THAT GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTION IS MODULATED AND CONDITION IS TREATED | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096453-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | CA12 113/4885CA2 1005/4885BBOX1 2887/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | CA12 122/4885CA2 929/4885BBOX1 2517/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | CA12 113/4885CA2 1005/4885BBOX1 2887/4885 |
| US-20020193395-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | CA12 122/4885CA2 929/4885BBOX1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.